Histamine and histamine receptor H1 (HRH1) axis: new target for enhancing immunotherapy response.
Ziyi Bai, Jiayuan Ai, Xiawei Wei
Author Information
- Ziyi Bai: Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.
- Jiayuan Ai: Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.
- Xiawei Wei: Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China. xiaweiwei@scu.edu.cn. ORCID
No abstract text available.
- Immunol Rev. 2017 Mar;276(1):66-79
[PMID: 28258694]
- Br J Pharmacol. 2020 Feb;177(3):516-538
[PMID: 30414378]
- Eur J Pharmacol. 2020 Jun 15;877:173090
[PMID: 32234529]
- Cancer Cell. 2022 Jan 10;40(1):36-52.e9
[PMID: 34822775]
- No. U19A2003/National Natural Science Foundation Regional Innovation and Development
- 32122052/National Science Foundation for Excellent Young Scholars
- No. 2019JDJQ008/Excellent Youth Foundation of the Sichuan Scientific Committee Grant
